Free Trial

BeiGene (BGNE) Stock Price, News & Analysis

+9.52 (+6.00%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
401,690 shs
Average Volume
234,271 shs
Market Capitalization
$16.09 billion
P/E Ratio
Dividend Yield
Price Target

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
49.9% Upside
$251.93 Price Target
Short Interest
1.63% of Shares Sold Short
Dividend Strength
News Sentiment
1.36mentions of BeiGene in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$10.16 M Sold Last Quarter
Proj. Earnings Growth
From ($8.20) to ($3.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.70 out of 5 stars

Medical Sector

412th out of 913 stocks

Pharmaceutical Preparations Industry

191st out of 429 stocks

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.93
Evaluating BeiGene: Insights From 6 Financial Analysts
BeiGene Becomes Oversold (BGNE)
4 Analysts Assess BeiGene: What You Need To Know
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.46 billion
Book Value
$37.10 per share


Free Float
Market Cap
$16.09 billion

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained


Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • BeiGene's revenue for the quarter increased by 67.9% year-over-year, indicating strong growth potential.
  • Positive analyst ratings with a consensus price target of $251.93, suggesting a favorable outlook for the stock.
  • Recent insider buying activity, indicating confidence in the company's future performance.
  • Development and commercialization of innovative oncology medicines, catering to a high-demand sector.
  • Current stock price trading at $160.77, potentially offering an entry point for investors seeking value.


Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • Analysts expect BeiGene, Ltd. to post a negative EPS of -8.2 for the current fiscal year, indicating potential financial challenges.
  • CEO and CFO selling significant amounts of company stock, which may raise concerns about insider sentiment.
  • Stock trading down 0.9% recently, signaling short-term market pressure on the company.
  • High volatility with a beta of 0.63, suggesting increased risk for investors compared to the market average.
  • 52-week high of $245.74 and low of $126.97, indicating price fluctuations that may impact investor confidence.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 9, 2024. Please send any questions or comments about these BeiGene pros and cons to

BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price target for 2024?

10 equities research analysts have issued twelve-month target prices for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they predict the company's stock price to reach $251.93 in the next twelve months. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2024?

BeiGene's stock was trading at $180.36 at the beginning of 2024. Since then, BGNE stock has decreased by 6.8% and is now trading at $168.11.
View the best growth stocks for 2024 here

Are investors shorting BeiGene?

BeiGene saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 1,560,000 shares, a decline of 6.6% from the May 15th total of 1,670,000 shares. Based on an average daily volume of 183,700 shares, the days-to-cover ratio is presently 8.5 days.
View BeiGene's Short Interest

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BGNE earnings forecast

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($2.41) EPS for the quarter, beating analysts' consensus estimates of ($3.07) by $0.66. The business earned $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative net margin of 28.39% and a negative trailing twelve-month return on equity of 21.70%. The business's revenue was up 67.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($3.34) earnings per share.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital International Investors (7.38%), Baillie Gifford & Co. (3.90%), Price T Rowe Associates Inc. MD (2.12%), Capital International Inc. CA (0.90%), Artal Group S.A. (0.42%) and Capital Group Private Client Services Inc. (0.22%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 6/12/2024 by Staff

From Our Partners